Clinical trial

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

NCT05675033

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-01-10

PhasePHASE2

Study timeline

Study start (estimated)2023-01-10Date precision: day

Registry last updated2023-01-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Adenocarcinomaunresolved

Stage IV Non-small Cell Lung Cancerunresolved

PD-1 Inhibitorunresolved

VEGFunresolved

Interventions

Serplulimab and Bevacizumab injectionDRUG

Sponsors & collaborators

Fujian Cancer Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05675033 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.